Sunday, August 09, 2020 3:37:02 PM
Assisting or even allowing Gilead to buy the 49% of CYDY is very dangerous.
At any time two or more shareholders can join forces and make a play for the company. I know of a company that two shareholders; each with 100 shares less than 5% joined forces. The two filed the SEC Docs, and fired the President, one became President and cut all non essential costs, raised working capital, fought off an acquisition, arranged a merger with a South African company in the same business as the largest division, and lastly sold the three divisions.
Meaning? With a much smaller position control was acquired and a new strategy chosen. Do we, the shareholders of CYDY wish to take the risk, as Chuckles just proved, that Gilead would or could bury Leron for HIV. This makes me sick. This is a sick game. Leron could be buried for Covid-19. Again sick.
After my experiences with Gilead ally Adam F, I have a very negative view of that company. I wish to ruin what remains of Adams reputation. Hope Adam receives this post and enjoys what I see heading his way.
Gilead has been correctly described as being in a very dangerous position. Short opportunity or maybe Puts would be more interesting.
At any time two or more shareholders can join forces and make a play for the company. I know of a company that two shareholders; each with 100 shares less than 5% joined forces. The two filed the SEC Docs, and fired the President, one became President and cut all non essential costs, raised working capital, fought off an acquisition, arranged a merger with a South African company in the same business as the largest division, and lastly sold the three divisions.
Meaning? With a much smaller position control was acquired and a new strategy chosen. Do we, the shareholders of CYDY wish to take the risk, as Chuckles just proved, that Gilead would or could bury Leron for HIV. This makes me sick. This is a sick game. Leron could be buried for Covid-19. Again sick.
After my experiences with Gilead ally Adam F, I have a very negative view of that company. I wish to ruin what remains of Adams reputation. Hope Adam receives this post and enjoys what I see heading his way.
Gilead has been correctly described as being in a very dangerous position. Short opportunity or maybe Puts would be more interesting.
Recent CYDY News
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
